NANEMIAR Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA
- Coordinator
- Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia, Spain
- Runs
- 1 October 2023 to 28 February 2027
- Status
- Running
- EU funding
- €2.7m
- Total cost
- €2.7m
- Partners
- 4 organisations in 3 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080156
What the project is doing
In the project's own words, from its summary on CORDIS.
Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity. Compared to DNA-based gene therapy, mRNA has significant advantages including higher intrinsic safety (non-integrating), lower cost of development, and less stringent regulatory requirements for clinical approval. In the NANEMIAR project, we take advantage of these benefits to kill 2 birds with 1 stone: first, we develop a first-of-its-kind nanomedicine for congenital anemia, a group of rare, inherited blood disorders characterized by ineffective red blood cell production.
Our proposed bone marrow-targeted mRNA-based therapy contributes to the first Horizon Europe strategic plan (2021-2024) for new and advanced therapies for non-communicable diseases and is expected to be a vast improvement over current treatment options in terms of efficacy and safety. Second, we provide critical knowledge on targeted non-viral polynucleotide delivery, with a platform that can be exploited for next-generation cell and gene therapy in a broader context.
To achieve this, our consortium combines the unique cell-targeting and mRNA knowledge from the Dutch Biotech Mercurna with two excellent research partners (from Spain and France) who have demonstrated expertise in the field of anemia. By focusing on the well-recognized rare disease model, beta-thalassemia, and combining an established mouse model, patient material, and previous drug development experience we build a convincing case to treat congenital anemia.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia | Murcia | Spain | Coordinator |
| Servicio Murciano De Salud | Murcia | Spain | Third party |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Mercurna BV | Nijmegen | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI